Improvement in pulmonary hemodynamics during intravenous epoprostenol (prostacyclin): A study of 15 patients with moderate to severe portopulmonary hypertension

Hepatology

Volumn 30, Issue 3, 1999, Pages 641-648

  Krowka, Michael J ^a   Frantz, Robert P ^a   Mcgoon, Michael D ^a   Severson, Cathy ^a   Plevak, David J ^b   Wiesner, Russell H ^a  

^a MAYO CLINIC   (United States)

^b DEPARTMENT OF UROLOGY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PROSTACYCLIN;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; DOPPLER ECHOCARDIOGRAPHY; FEMALE; HEART CATHETERIZATION; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LUNG ARTERY PRESSURE; LUNG HEMODYNAMICS; MALE; PORTAL HYPERTENSION; PRIORITY JOURNAL; PULMONARY HYPERTENSION;

ADULT; AGED; EPOPROSTENOL; FEMALE; HEMODYNAMIC PROCESSES; HUMANS; HYPERTENSION, PULMONARY; LIVER TRANSPLANTATION; LUNG; MALE; MIDDLE AGED; PROSPECTIVE STUDIES;

EID: 0032870286     PISSN: 02709139     EISSN: None     Source Type: Journal    
DOI: 10.1002/hep.510300307     Document Type: Article

References (24)

1. Rich S, Dantzker DR, Ayers SM, Bergofsky EH, Brundage BH, Detre KM, Fishman AP. Primary pulmonary hypertension: a national prospective study. Ann Intern Med 1987;107:216-223.
2. Herve P, Lebrec D, Brenot F, Simonneau G. Humbert M. Sitbon O, Duroux P. Pulmonary vascular disorders in portal hypertension. Eur Respir J 1998;11:1153-1166.
3. Kuo PC, Plotkin JS, Rubin LJ. Distinctive clinical features of porlopulmonary hypertension. Chest 1997;112:980-986.
4. Edwards BS, Weir EK, Edwards WD, Ludwig J, Dykaski RK, Edwards JE. Co-existent pulmonary and portal hypertension: morphologic and clinical features. J Am Coll Cardiol 1987;10:1233-1238.
5. Krowka MJ. Hepatopulmonary hypertension and portopulmonary hypertension: distinctions and dilemmas. HEPATOLOGY 1997;25:1282-1284.
6. Edwards WD. Pulmonary hypertension and related diseases. In: Stehbeus WE, Lie JT, eds. Vascular Pathology. London: Chapman and Hall Medical, 1995:585-621.
7. Martinez EJ, Wright RK, Schiff ER, Tzakis AG, Krowka MJ. Portopulmonary hypertension and liver transplantation: why we fail. HEPATOLOGY 1996;24:186A.
8. Robalino BD, Moodie DS. Association between primary pulmonary hypertension and portal hypertension: analysis of its pathophysiology, clinical laboratory, and hemodynamic manifestations. J Am Coll Cardiol 1991;17:492-499.
9. Mandell MS, Groves BM. Pulmonary hypertension in chronic liver disease. Clin Chest Med 1996;17:17-33.
10. Barst RJ, Rubin LJ, Long WA, McGoon MD, Rich S, Badesch DB, Groves MB, et al. A comparison of continuous intravenous epoprostenol (prostacyclin) with conventional therapy for primary pulmonary hypertension. N Engl J Med 1996;334:296-301.
11. McLaughlin W, Genthner DE, Panella MM, Rich S. Reduction in pulmonary vascular resistance with long term epoprostenol (prostacyclin) therapy in primary pulmonary hypertension. N Engl J Med 1998;338:272-277.
12. Kim R, Krowka MJ, Plevak DJ, Frantz R, Wiesner RH. Moderate to severe portopulmonary hypertension: important correlates with Doppler echocardiography in liver transplant patients. HEPATOLOGY 1998;28:759A.
13. Rubin LJ, Groves BM, Reeves JT, Frosolano M, Handel F, Cato AE. Prostacyclin-induced acute pulmonary vasodilatation in primary pulmonary hypertension. Circulation 1982;2:334-338.
14. Groves BM, Rubin LJ, Frosolano MF, Cato AE, Reeves JT. A comparison of acute hemodynamic effects of prostacyclin and hydralazine in primary pulmonary hypertension. Am Heart J 1985;110:1200-1204.
15. Jones DK, Higenbottam TW, Wallwork J. Treatment of primary pulmonary hypertension with intravenous epoprostenol (prostacyclin). Br Heart J 1987;57:270-278.
16. Weir EK, Rubin LJ, Ayres SM, Bergofsky EH, Brundage BH, Detre KM, Elliot CG, et al. The acute administration of vasodilators in primary pulmonary hypertension. Am Rev Respir Dis 1989;140:1623-1630.
17. Palevsky HI, Long W, Crow J, Fishman AP. Prostacyclin and acetlycholine as screening agents for acute pulmonary vasodilator responsiveness in primary pulmonary hypertension. Circulation 1990;82:2018-2026.
18. Nootens M, Schrader B, Kaufmann E, Vestal R, Long W, Rich S. Comparative acute effects of adenosine and prostacyclin in primary pulmonary hypertension. Chest 1995;107:54-57.
19. Raffy O, Azarian R, Brenot F, Parent F, Sitbon O, Petitpretz P, Herve P, et al. Clinical significance of pulmonary vasodilator response during short-term infusion of prostacyclin in primary pulmonary hypertension. Circulation 1996;93:484-488.
20. Palevsky HI, Fishman AP. The management of primary pulmonary hypertension. JAMA 1991;8:1014-1020.
21. Botney MD. Role of hemodynamics in pulmonary vascular remodeling. Am J Respir Crit Care Med 1999;159:361-364.
22. Kuo PC, Plotkin JS, Howell CD, Bartlett ST, Rubin LJ. Continuous infusion of epoprostenol for the treatment of portopulmonary hypertension. Transplantation 1997;63:604-606.
23. Plotkin JS, Kuo PC, Rubin LJ, Gaine S, Howell CD, Laurin J, Njoku MJ, et al. Successful use of chronic epoprostenol as a bridge to liver transplantation in severe portopulmonary hypertension. Transplantation 1998;65:457-459.
24. Ramsay MAE, Simpson BR, Nguyen AT, Ramsay K, East C, Klintmalm GB. Severe hypertension in liver transplant candidates. Liver Transplant Surg 1997;3:494-500.